Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility

• ClinicalTrials.gov Identifier: NCT01617395
• Recruitment Status: Completed
• First Posted: June 12, 2012
• Last Update Posted: November 13, 2019
• Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
• Information provided by (Responsible Party): National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) )

Tracking Information

• First Submitted Date: June 8, 2012
• First Posted Date: June 12, 2012
• Last Update Posted Date: November 13, 2019
• Actual Study Start Date: August 15, 2012
• Primary Completion Date: Not Provided

Current Primary Outcome Measures (submitted: November 8, 2019)

• presence or absence of lesions on T2-weighted brain MRI [ Time Frame: ongoing ]
  For participants in the cross-sectional cohort, which consists of individuals at highest and lowest risk for MS, the primary outcome measure is the presence or absence of lesions on T2-weighted brain MRI that meet the 2010 MRI criteria for dissemination in space
• GERS [ Time Frame: ongoing ]
  For participants in the overall GEMS study, the primary outcome measure is the GERS itself, as most participants in this cohort will not undergo further testing

• Original Primary Outcome Measures: Not Provided
• Change History: Complete list of historical versions of study NCT01617395 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures (submitted: November 8, 2019)

• development of MS-like abnormalities on brain imaging studies, abnormalities on laboratory testing, and clinical symptoms and signs. [ Time Frame: ongoing ]
  The age at which participants develop MS-related abnormalities on brain imaging studies, abnormalities on laboratory testing, andclinical symptoms and signs;
• The time lag between defined exposures [ Time Frame: ongoing ]
  time lag between defined exposures (for example, infectious mononucleosis) and the appearance of MS-related radiological, laboratory, and clinical abnormalities
• The time lag between the appearance of asymptomatic radiological and laboratory abnormalities and the onset of clinical symptoms; [ Time Frame: ongoing ]
  The time lag between the appearance of asymptomatic radiological and laboratory abnormalities and the onset of clinical symptoms;
• exploratory clinical, imaging, biological data in the crosssectional [ Time Frame: ongoing ]
  exploratory clinical, imaging, and biological data in the cross sectional that may suggest subclinical MS disease activity

• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility
• Official Title: Integrating Genetic and Environmental Risk Scores Into an Algorithm to Predict Multiple Sclerosis Susceptibility

Brief Summary

Background:

- Research shows that both genes and the environment influence a person s risk for getting multiple sclerosis (MS). However, it is not possible to accurately predict who will develop MS. Researchers want to study people with MS and their family members. They have developed a Genetic and Environmental Risk Score for MS. This score combines information from a person's medical history and genes. It also includes environmental factors that may be related to developing MS. This study will test this risk score to see if it can help predict who will develop MS.

Objectives:

- To evaluate a score for genetic and environmental risk factors that may help predict whether a person will develop MS.

Eligibility:

• Individuals at least 18 years of age who have MS.
• Individuals between 18 to 50 years of age who are the parent, brother, sister, or child of a person with MS.

Design:

• People with MS will allow researchers to look at their personal and medical data. These data will have been collected in other MS-related studies.
• Relatives of people with MS will fill out a questionnaire and give blood and saliva samples. They will fill out the questionnaire again one year later.
• Some relatives will have additional optional testing. These tests will include a physical exam and imaging studies. There may also be other tests. These tests may be repeated every 1 to 5 years for 20 years.

Detailed Description

Objective. The overall objective of this study is to investigate the genetic, immune, and neuroimaging profiles that may increase a person s risk of developing multiple sclerosis (MS) in order to identify and validate predictive biomarkers in populations at risk for this disorder.

Study population. There will be three study populations:

1. Individuals at risk for developing MS As part of the Genes and Environment in Multiple Sclerosis (GEMS) study, we plan to recruit up to 1000 first-degree relatives of MS patients. GEMS is a study aiming to recruit 5000 individuals that is being led by our collaborators at Columbia University Medical Center. For the purposes of this study, a first-degree relative may be a parent, sibling, or child between 18 and 50 years of age but must not carry a diagnosis of MS. The first-degree relative must have the ability to provide consent and be willing to participate in the study. Two potentially overlapping subsets of these individuals will undergo detailed testing at the NIH:

   1. The cross-sectional subcohort will consist of up to 150 participants with combined genetic and environmental risk scores (GERS), defined in the protocol, in the highest and lowest 20 percent of the entire study population. Selected participants may be invited for follow-up studies based on data obtained at baseline if symptoms develop.
   2. The NINDS longitudinal subcohort will consist of up to 10 participants, ages 18 to 40,who express willingness to be followed for 20 years at the NIH, whose GERS falls in the top 20 percent of the entire study population, and who have a first-degree relative with MS who is participatipate
2. MS patients - We plan to recruit up to 1000 MS patients whose first-degree relatives are enrolled this study. These participants either: (A) will be evaluated under other Neuroimmunology Branch Clinic protocols and will not undergo separate evaluation under this protocol; or (B) will send us medical records confirming their MS diagnosis via mail/fax/secure email, without the requirement to participate in another NIH protocol. The purpose of including this cohort in the current study is to allow access to their clinical, biological, and imaging data for comparison with first-degree relatives, if available, and to confirm that existing GEMS participants have a first-degree relative diagnosed with MS.
3. Healthy volunteers - We plan to recruit up to 80 healthy volunteers, ages 18-50, who do not have a known first-degree relative with MS. The purpose of including this cohort in the current study is to allow quantification of the degree and extent of abnormalities, including abnormalities of the blood-brain barrier, in individuals at risk for developing MS. Without imaging data obtained from healthy volunteers, there is no way to determine whether subtle clinical and neuroimaging findings in the at-risk cohort are truly abnormal, or to correctly threshold and quantify the observed abnormalities.

Design. This is a prospective cohort natural-history study. All GEMS participants will complete the following study procedures, which can be performed offsite: informed consent; study questionnaire; saliva sample; and blood draw. The questionnaire will be repeated 1 year after enrollment.

There will two additional substudies conducted at NIH: a cross-sectional substudy and a longitudinal substudy. Participants in these substudies will be evaluated with clinical, radiological, and laboratory procedures. Participants in the cross-sectional cohort will undergo evaluation at the NIH at a single time point (with optional longitudinal follow up), whereas participants in the longitudinal cohort will undergo evaluation at the NIH for 20 years. There will be an interim analysis 5 years after the 50th participant is recruited to the longitudinal cohort, and the study of this cohort may be terminated if we have not observed the development of MS-related radiological or laboratory abnormalities in any of the participants. Participants with MS will provide informed consent to allow access to their own research data, but the data themselves will be (or will have already been) collected under other Neuroimmunology Clinic clinical protocols.

NIH is a unique site within the overall GEMS study, for the following reasons: (1) It is the only site at which imaging is being performed, as part of the cross-sectional and longitudinal substudies; (2) GEMS participants seen at NIH may undergo additional procedures that are not part of the overall GEMS study; (3) Data from participants in the NIH substudy will be directly linked to data from their own relatives with MS.

Outcome measures. For participants in the overall GEMS study, the primary outcome measure is the GERS itself, as most participants in this cohort will not undergo further testing. For participants in the cross-sectional cohort, which consists of individuals at highest and lowest risk for MS, the primary outcome measure is the presence or absence of lesions on T2-weighted brain MRI that meet the 2010 MRI criteria for dissemination in space - a finding that, in this population, may well be related to MS. For participants in the longitudinal cohort, the study endpoint is a clinical diagnosis of MS according to the same 2010 criteria. Secondary outcome measures include: (1) The age at which participants develop MS-related abnormalities on brain imaging studies, abnormalities on laboratory testing, and clinical symptoms and signs; (2) The time lag between defined exposures (for example, infectious mononucleosis) and the appearance of MS-related radiological, laboratory, and clinical abnormalities; (3) The time lag between the appearance of asymptomatic radiological and laboratory abnormalities and the onset of clinical symptoms; and (4) Additional exploratory clinical, imaging, and biological data in the crosssectional that may suggest subclinical MS disease activity.

• Study Type: Observational
• Study Design: Observational Model: Cohort; Time Perspective: Prospective
• Target Follow-Up Duration: Not Provided
• Biospecimen: Not Provided
• Sampling Method: Non-Probability Sample
• Study Population: Primary clinical
• Condition: Multiple Sclerosis
• Intervention: Not Provided

Study Groups/Cohorts

• GEMS cohort
  Individuals at risk for developing MS
• Healthy Volunteer Cohort
  Healthy volunteers, ages 18-50, who do not have a known first-degree relative with MS
• MS Patients Cohort
  MS patients whose first-degree relatives are enrolled in this study

Publications *

• Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernán MA, Olek MJ, Hankinson SE, Hunter DJ. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA. 2001 Dec 26;286(24):3083-8.
• Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med. 2006 Mar 23;354(12):1273-80. Review.
• Chiappa KH. Use of evoked potentials for diagnosis of multiple sclerosis. Neurol Clin. 1988 Nov;6(4):861-80. Review.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: November 8, 2019): 181
• Original Estimated Enrollment (submitted: June 8, 2012): 2000
• Study Completion Date: Not Provided
• Primary Completion Date: Not Provided

Eligibility Criteria

• INCLUSION CRITERIA:

GEMS cohort (target n equals 1000)

• First-degree relative (parent, sibling, or child) of a self-reported MS patient.
• Age 18-50, inclusive, at the time of enrollment into the overall GEMS study.
• Willingness to be contacted regarding additional follow-up procedures.

• Cross-sectional subcohort (target n equal 150):

  • Referred by Columbia University Medical Center as having a genetic and environmental risk score (GERS), defined in Section 4.1.1, in the top or bottom 20% of the overall GEMS study.

• NINDS Longitudinal subcohort (target n equal 100):

  • Ages 18-40, inclusive.
  • Referred by Columbia University Medical Center as having a GERS in the top 20% of the overall GEMS study.
  • Willing to undergo additional study procedures at the NIH for up to 20 years, with planned follow-up every year for participants between ages 18 and 25, every 2 years for participants between ages 26 and 30, and every 5 years for participants between ages 31 and 40.
  • Relative enrolled in NIH study with confirmation of MS diagnosis.

MS patient cohort (target n=1000):

• MS patients (NIH)

  • Co-enrolled in another Neuroimmunology Clinic natural history protocol.
  • Diagnosis confirmed at NIH.
  • Age 18 or older.

• MS patient (non-NIH)

  • First-degree relative (parent, sibling, or child) of an existing GEMS participant.
  • Able and willing to send medical records associated with their MS diagnosis to NIH.

• Healthy volunteer cohort (target n=80)

  • Age 18-50, inclusive.
  • No known first-degree relative (parent, sibling, or child) with MS.

• All cohorts

  • Able to give informed consent.

EXCLUSION CRITERIA:

GEMS cohort

-Diagnosis of MS.

Cross-sectional and NINDS longitudinal subcohorts

• Contraindications to MRI scanning.
• Diagnosis of another central nervous system disease disease (CNS neoplasm, known cerebrovascular disease, known CNS degenerative diseases, or known CNS inflammatory diseases) at the time enrollment into the study.

• MS cohort (both)

  --None

• Healthy volunteer cohort

  • Diagnosis of MS or another central nervous system (CNS neoplasm, cerebrovascular disease CNS degenerative diseases, or CNS inflammatory diseases) or a systemic disease that would interfere with the aims of this study.
  • Contraindications to MRI scanning.

Eligible NIH employees and staff may participate.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 50 Years (Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT01617395
• Other Study ID Numbers: 120122; 12-N-0122
• Has Data Monitoring Committee: Not Provided

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Responsible Party: National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) )
• Study Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
• Collaborators: Not Provided

Investigators

• Principal Investigator: Daniel S Reich, M.D.; National Institutes of Health Clinical Center (CC)

• PRS Account: National Institutes of Health Clinical Center (CC)
• Verification Date: November 7, 2019